Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide.

ABSTRACT:

Background

The prevalence of chronic kidney disease (CKD) in patients with inflammatory bowel disease (IBD) is increasing. The pharmacokinetic profiles of IBD medications in patients with advanced-stage CKD are not well studied.

Aim

To provide evidence-based guidance on the use of medical therapies in patients with IBD and CKD.

Methods

We conducted a narrative review of literature up to 31 March 2025 on studies of therapies currently used for the treatment of IBD in the setting of CKD, with a focus on advanced kidney disease and use in renal replacement therapy.

Results

Mesalazine can cause acute interstitial nephritis. Calcineurin inhibitors have been associated with nephrotoxicity. Methotrexate is contraindicated in advanced renal disease, including while on

SUBMITTER: Chen L 

PROVIDER: S-EPMC12287904 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature